Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD1480 · 1 trial · 3 indications
Single dose AUC0-12 (ug\*h/L)
Single dose AUC0-24 (ug\*h/L)
Single dose AUC(0 to infinity) (ug\*h/L)
Multiple dose Cmax,ss (ug/L)
Multiple dose Cmin,ss (ug/L)
Single dose Cmax (ug/L)
Single dose Vz/F (L)
Single dose CL/F (L/h)
Multiple dose CLss/F (L/h)
Single dose Tmax (h)
Multiple dose Tmax,ss (h)
PSTAT3 inhinition
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD1480 |
| Name | Type | Description |
|---|---|---|
| AZD1480 | DRUG | Oral capsule 2.5 mg, 10 mg and 40 mg |
Inclusion Criteria: * Patients with myelofibrosis requiring therapy * Evidence of post-menopausal status or sterile * ECOG Performance Status \</=2 Exclusion Criteria: * Prior therapy with any JAK2 medications * Significant lung disorder or lung disease * Previous radiation therapy to chest wall ...
AZD1480 was studied for the treatment of myeloproliferative diseases, with primary myelofibrosis (PMF) as its lead indication. Its single clinical trial also enrolled patients with post-polycythaemia vera myelofibrosis and essential thrombocythaemia myelofibrosis. It is an investigational agent and is not an approved therapy.
AZD1480 targets JAK2, a Janus kinase. It is a small molecule JAK2 inhibitor, meaning it acts by blocking the activity of this kinase. JAK2 inhibition was the intended mechanism in the myeloproliferative disease setting studied for this compound.
AZD1480 was developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. The compound is a small molecule JAK2 inhibitor that the company advanced into clinical testing in oncology, specifically in myeloproliferative diseases.
AZD1480 reached Phase 1 clinical development. It is an investigational drug and has not been approved for any indication. The Phase 1 program has been completed, and no trials of AZD1480 are currently active.
AZD1480 was evaluated in one completed Phase 1 trial, NCT00910728, titled a study to assess the safety of AZD1480 in patients with myeloproliferative diseases. That trial enrolled 65 patients across the United States and France and included adults aged 25 years and older.
The AZD1480 Phase 1 trial NCT00910728 was an uncontrolled, open-label study, not randomized and not double blinded. It enrolled 65 patients with myeloproliferative diseases, including primary myelofibrosis, post-polycythaemia vera myelofibrosis, and essential thrombocythaemia myelofibrosis, and it has been completed.